person · Reporting owner

Meikle Phillip Terry II

Disclosed activity across 1 company

Tapewire entity: 78808
SEC CIK: 0002041874

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bone Biologics CorpBBLG · Entity 8560	Director	September 28, 2026	September 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bone Biologics Corp

Report date September 28, 2026 · Filed September 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2036-09-28	Direct	113,896	Reported balance After 2026-09-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-28 · Grant · Acquired 113,896 · Balance 113,896 F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-06-04	Direct	10,483	Reported balance Holding disclosure · report date 2026-09-28 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 10,483 F2: This option is fully exercisable as of the date of this report.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.28 · Expires 2034-10-16	Direct	4,698	Reported balance Holding disclosure · report date 2026-09-28 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 4,698 F2: This option is fully exercisable as of the date of this report.
Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.28 · Expires 2034-10-16	Direct	2	Reported balance Holding disclosure · report date 2026-09-28 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 2 F2: This option is fully exercisable as of the date of this report.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

F2: This option is fully exercisable as of the date of this report.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 28, 2026 Filed Sep 30, 2026 21:09 UTC	Bone Biologics Corp BBLG · Entity 8560	GrantNon-Employee Stock Option · Derivative	113,896	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0001493152-26-045140 · ownership.xml · derivative · entry 1 Meikle Phillip Terry II · CIK 0002041874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,896 Underlying: Common Stock · 113,896 shares Expires 2036-09-28 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. Read SEC document
June 04, 2025 Filed Jun 6, 2025 17:01 UTC	Bone Biologics Corp BBLG · Entity 8560	GrantNon-Employee Stock Option · Derivative	62,894	$0.00 Strike: $0.88	$0.00	Disclosure SEC source: 0001641172-25-014099 · ownership.xml · derivative · entry 1 Meikle Phillip Terry II · CIK 0002041874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,894 Underlying: Common Stock · 62,894 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments. Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:27 UTC	Bone Biologics Corp BBLG · Entity 8560	GrantNon-Employee Stock Option · Derivative	28,185	$0.00 Strike: $1.88	$0.00	Disclosure SEC source: 0001493152-24-041658 · ownership.xml · derivative · entry 2 Meikle Phillip Terry II · CIK 0002041874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,185 Underlying: Common Stock · 28,185 shares Expires 2034-10-16 F2 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vesting and becoming exercisable in four equal installments on 12/17/24, 3/19/25, 6/19/25 and 9/17/25. Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:27 UTC	Bone Biologics Corp BBLG · Entity 8560	GrantNon-Employee Stock Option · Derivative	9	$0.00 Strike: $1.88	$0.00	Disclosure SEC source: 0001493152-24-041658 · ownership.xml · derivative · entry 1 Meikle Phillip Terry II · CIK 0002041874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9 Underlying: Common Stock · 9 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.